ORAMED PHARMACEUTICALS INC. Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations
ORAMED PHARMACEUTICALS INC. (ORMP) reported Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations of 130.71 thousand shares for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-27.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations · last filed 2025-03-27
- ORAMED PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, expirations for fiscal 2023 was 130.71K shares, a 3666.71% increase from fiscal 2022.
- ORAMED PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, expirations for fiscal 2022 was 3.47K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations 12 month |
|---|---|
| 2023-12-31 | 130.71K shares 10-K · filed 2025-03-27 |
| 2022-12-31 | 3.47K shares 10-K · filed 2024-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |